Do not freeze unless specified by product labeling or lab SOPs
Giese finds that patients who drop 30 pounds or more with semaglutide usually want to stay on a small maintenance dose

The report details the birth of one healthy child and another pregnancy resulting in a child with an atrial septal defect, which spontaneously resolved by the age of 3 years.8 One single case of exposure to semaglutide in early pregnancy due to off-label treatment for polycystic ovary syndrome (PCOS) was reported with no birth defect.9 Another case of exposure to dulaglutide during the first trimester of pregnancy for the treatment of type 2 diabetes did not result in any reported birth defects.10 Due to the paucity of data concerning semaglutide and human pregnancy outcomes, the manufacturer advises stopping this treatment 2 months before conception.11 In a multinational population-based cohort study involving 51,826 pregnant women diagnosed with type 2 diabetes and their infants, the standardised prevalence of major congenital malformations was 8.3% among infants with periconceptional exposure to GLP1-RA (n=938).12 Compared with insulin, there was no increased risk of major congenital malformations (adjusted relative risk 0.95, 95% CI, 0.72 to 1.26) for infants exposed to GLP1-RA

An Ecological Momentary Assessment Study with the "TrackYourTinnitus" Application
Common reported side-effects: Pain or redness at the injection site Rare swelling at the injection site Rarely reported side effects include: Dizziness Flushing Headaches Sleepiness Hyperactivity Re-test date for IGF-1 in 3 mos to ensure proper growth hormone levels after treatment If you have any questions or concerns, please call our office
resM GLP-1 postbiotic: real user reviews and experiences The product currently holds a 4.8-star rating across roughly 1,286 reviews, which is strong by any supplement standard